Bilyana Stoilova
PhD, MSc, BSc
Project Manager
I joined OVG in December 2021 as a Project manager to ensure projects are delivered on time, within budget and in compliance with regulatory requirements.
Before joining OVG, from 2008 till 2013 I was a scientist at the Cell Differentiation and Tumorigenesis research group headed by Prof Achim Leutz and was awarded a PhD fellowship from the International PhD Program at Max Delbruck Center for Molecular Medicine and Humboldt University, Berlin, Germany.
After completing my PhD, I worked as a postdoctoral researcher at Prof Paresh Vyas research group Biology and Treatment of Human Myeloid Cancers at the MRC Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine. I worked on research projects aiming to understand the mechanisms of blood cell development and how these mechanisms get deregulated in leukaemia.
Recent publications
-
A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.
Conference paper
Lachowiez CA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39
-
Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
Journal article
Juban G. et al, (2021), Haematologica, 106, 1106 - 1119
-
Mechanisms of response and resistance to AML therapies
Journal article
Stoilova B. et al, (2020), Clinical Lymphoma, Myeloma & Leukemia, 20, S7 - S7
-
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax plus /- azacitidine in IDH1-mutated hematologic malignancies.
Conference paper
Lachowiez CA. et al, (2020), JOURNAL OF CLINICAL ONCOLOGY, 38
-
C/EBPalpha and GATA-2 mutations induce bi-lineage acute erythroid leukemia through transformation of a neomorphic neutrophil-erythroid progenitor
Journal article
NERLOV C. et al, (2020), Cancer Cell